EVALUATION OF NEUTROPHIL FLUORESCENCE IN PATIENTS WITH DISSEMINATED INTRAVASCULAR COAGULATION ASSOCIATED WITH SEPTIC SHOCK
Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · Jun 17, 2025
Trial Information
Current as of June 28, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help diagnose a serious condition called disseminated intravascular coagulation (DIC) that can happen in patients with septic shock—a life-threatening response to infection. The researchers are looking at whether measuring a special glow (called fluorescence) in certain white blood cells (neutrophils) can reliably and quickly detect DIC. Their goal is to find the right level of this glow that correctly identifies at least 90% of patients with this condition, which could help doctors diagnose and treat it sooner.
Adults 18 years and older who are in the intensive care unit with septic shock may be eligible to participate, as long as they don’t have certain other health issues like severe liver disease, very low white blood cell counts, or are pregnant or breastfeeding. Patients need to be able to give consent, or if they can’t, a family member may provide it, or emergency procedures may be used if no family is available. Participants can expect tests that measure neutrophil fluorescence, which is a blood test, to help the researchers understand if this method works well. This study is not yet recruiting, but it aims to improve early diagnosis of DIC in very sick patients, potentially leading to better care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female ≥ 18 years of age
- • Patient admitted to intensive care for septic shock
- • Patient affiliated to a social security scheme or entitled to it
- • Non-opposition by the patient or a relative in the event that the patient is not in a state to express his or her consent or inclusion in an emergency procedure in the event that the patient is not in a state to express his or her opinion and no relative of the patient can be reached.
- Exclusion Criteria:
- • Dying patient on the day of inclusion
- • Cirrhosis Child Pugh C
- • Neutropenia (\<500 mm3)
- • Patient under judicial protection
- • Patient under guardianship or curatorship
- • Pregnancy
- • Breastfeeding
About University Hospital, Strasbourg, France
The University Hospital of Strasbourg, France, is a leading academic medical center renowned for its commitment to advancing healthcare through innovative clinical research and patient-centered care. As a prominent sponsor of clinical trials, the institution collaborates with a diverse range of healthcare professionals and research teams to explore cutting-edge therapies and treatment modalities. With state-of-the-art facilities and a multidisciplinary approach, the University Hospital of Strasbourg plays a pivotal role in translating scientific discoveries into effective clinical applications, contributing significantly to the advancement of medical knowledge and improved patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Strasbourg, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported